> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Endo Recalls Robaxin Due to Labeling Error
- URL: https://www.fdaweb.com/endo-recalls-robaxin-due-to-labeling-error/
- Published: 2018-10-01T12:00:00.000Z
- Updated: 2026-09-15T00:35:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142477

Endo International has recalled two lots of Robaxin (methocarbamol tablets, USP) 750mg tablets in 100-count bottle packs due to some products having incorrect daily dosing information on the label. A labeling error misstates the daily dose as “two to four tablets four times daily” rather than the correct dosage of “two tablets three times daily,” a recall [notice](https://www.fda.gov/Safety/Recalls/ucm622008.htm?ref=fdaweb.com) says.  

“Patients who follow the directions on the bottle may experience significant drowsiness or dizziness which would put them at risk of falls or an overdose which could result in seizures, coma, or death,” the notice says. To date, Endo says it has not received any reports of adverse events related to the recall.

  
Robaxin is indicated as an adjunct therapy to rest, physical therapy and other measures for relieving discomfort associated with acute, painful musculoskeletal conditions.